Title (en)

PHOSPHATE SALTS OF 6-DIMETHYLAMINOMETHYL-L-(3-METHOXYPHENYL) -1,3-DIHYDROXYCYCLOHEXANE COMPOUNDS

Title (de)

PHOSPHATSALZE DER 6-DIMETHYLAMINOMETHYL-L- (3-METHOXYPHENYL) -1,3-DIHYDROXY- CYCLOHEXANVERBINDUNGEN

Title (fr)

SELS DE PHOSPHATE DES COMPOSES 6-DIMETHYLAMINOMETHYL-L-(3-METHOXYPHENYLE)-1,3-DIHYDROXY-CYCLOHEXANE

Publication

EP 1851191 A1 20071107 (DE)

Application

EP 06707123 A 20060221

Priority

- EP 2006001547 W 20060221
- DE 102005009217 A 20050225

Abstract (en)

[origin: DE102005009217A1] Phosphoric acid salt of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxycyclohexane compound (I) (where the phosphoric acid is preferably diphosphoric acid and/or orthophosphoric acid), is new. Phosphoric acid salts of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxycyclohexane compound of formula (I) (where the phosphoric acid is preferably diphosphoric acid and/or orthophosphoric acid), are new. R 2>, R 3> = OH or H. Independent claims are also included for: (1) preparation of (I); (2) polymorph A of (I) in the orthophosphate salt form having X-ray powder diffraction (XRPD) as given in the specification and measured with copper potassium (CuK) alpha radiation or by a Raman spectrum with excitation wavelength of 1064 nm as given in the specification; (3) polymorph B of (I) in the orthophosphate salt form having XRPD as given in the specification and measured with CuK-alpha radiation or by a Raman spectrum with excitation wavelength of 1064 nm; (4) polymorph C of (I) in the orthophosphate salt form having XRPD as given in the specification of table 3 and measured with CuK-alpha radiation or by a RAMAN spectrum with excitation wavelength of 1064 nm as given in the specification; (5) polymorph amorphous (I) in the orthophosphate salt form having XRPD as given in the specification and measured with CuK-alpha radiation, and (6) preparation of one or more polymorphs. [Image] ACTIVITY : Analgesic; Antimigraine; Antidepressant; Neuroprotective; Nootropic; Antiparkinsonian; Anticonvulsant; Tranquilizer; Antitussive; Uropathic; Antidiarrheic; Antipruritic; Neuroleptic; Cerebroprotective; Vasotropic; Immunomodulator; Anabolic; Eating-Disorders-Gen.; Antialcoholic; Antiaddictive; Gastrointestinal-Gen. No biological data is given. MECHANISM OF ACTION : None given.

IPC 8 full level

C07C 217/54 (2006.01); **A61K 31/135** (2006.01)

CPC (source: EP KR)

A61K 31/135 (2013.01 - KR); **A61P 1/12** (2017.12 - EP); **A61P 1/14** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 7/10** (2017.12 - EP); **A61P 7/12** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/14** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 21/02** (2017.12 - EP); **A61P 23/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/26** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/30** (2017.12 - EP); **A61P 25/32** (2017.12 - EP); **A61P 25/34** (2017.12 - EP); **A61P 25/36** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **C07C 217/54** (2013.01 - KR); **C07C 217/56** (2013.01 - KR); **C07C 217/74** (2013.01 - EP KR); C07C 2601/14 (2017.04 - EP)

Citation (search report)

See references of WO 2006089707A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

HR

DOCDB simple family (publication)

DE 102005009217 A1 20060831; AR 053145 A1 20070425; AU 2006218132 A1 20060831; AU 2006218132 B2 20111006; BR PI0606146 A2 20090602; CA 2598845 A1 20060831; CN 101137615 A 20080305; EP 1851191 A1 20071107; IL 185468 A0 20080106; JP 2008531510 A 20080814; KR 20070107162 A 20071106; MX 2007010361 A 20080221; NO 20074673 L 20071019; NZ 556338 A 20091127; PE 20061100 A1 20070104; RU 2007135271 A 20100227; TW 200640840 A 20061201; WO 2006089707 A1 20060831; ZA 200708153 B 20081029

DOCDB simple family (application)

DE 102005009217 A 20050225; AR P060100684 A 20060224; AU 2006218132 A 20060221; BR PI0606146 A 20060221; CA 2598845 A 20060221; CN 200680005964 A 20060221; EP 06707123 A 20060221; EP 2006001547 W 20060221; IL 18546807 A 20070823; JP 2007556542 A 20060221; KR 20077021974 A 20070921; MX 2007010361 A 20060221; NO 20074673 A 20070913; NZ 55633806 A 20060221; PE 2006000228 A 20060227; RU 2007135271 A 20060221; TW 95104476 A 20060210; ZA 200708153 A 20070921